GeoVax Labs マネジメント

マネジメント基準チェック /44

GeoVax Labsの CEO はDavid Doddで、 Sep2018年に任命され、の在任期間は 6.17年です。の年間総報酬は$ 384.20Kで、 96.6%給与と3.4%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.28%を直接所有しており、その価値は$ 78.65K 。経営陣と取締役会の平均在任期間はそれぞれ3.5年と14.7年です。

主要情報

David Dodd

最高経営責任者

US$384.2k

報酬総額

CEO給与比率	96.6%
CEO在任期間	6.2yrs
CEOの所有権	0.3%
経営陣の平均在職期間	3.5yrs
取締役会の平均在任期間	14.7yrs

経営陣の近況

Recent updates

GeoVax: A Legitimate COVID-19 Phase 2 Vaccine Candidate Trading At Only A $25 Million Valuation

Dec 27

We Think GeoVax Labs (NASDAQ:GOVX) Can Afford To Drive Business Growth

Nov 27

GeoVax: Expands Immuno-Oncology Pipeline With Clinical-Stage Program

Oct 03

We Think GeoVax Labs (NASDAQ:GOVX) Can Afford To Drive Business Growth

Aug 14

Did Business Growth Power GeoVax Labs' (NASDAQ:GOVX) Share Price Gain of 111%?

Feb 18

GeoVax soars on NIAID grant for COVID-19 vaccine candidate

Jan 11

CEO報酬分析

GeoVax Labs の収益と比較して、David Dodd の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$24m
Jun 30 2024	n/a	n/a	-US$27m
Mar 31 2024	n/a	n/a	-US$28m
Dec 31 2023	US$384k	US$371k	-US$26m
Sep 30 2023	n/a	n/a	-US$24m
Jun 30 2023	n/a	n/a	-US$19m
Mar 31 2023	n/a	n/a	-US$16m
Dec 31 2022	US$652k	US$309k	-US$14m
Sep 30 2022	n/a	n/a	-US$22m
Jun 30 2022	n/a	n/a	-US$20m
Mar 31 2022	n/a	n/a	-US$19m
Dec 31 2021	US$677k	US$250k	-US$19m
Sep 30 2021	n/a	n/a	-US$6m
Jun 30 2021	n/a	n/a	-US$5m
Mar 31 2021	n/a	n/a	-US$4m
Dec 31 2020	US$727k	US$250k	-US$3m
Sep 30 2020	n/a	n/a	-US$2m
Jun 30 2020	n/a	n/a	-US$2m
Mar 31 2020	n/a	n/a	-US$2m
Dec 31 2019	US$251k	US$250k	-US$2m
Sep 30 2019	n/a	n/a	-US$2m
Jun 30 2019	n/a	n/a	-US$3m
Mar 31 2019	n/a	n/a	-US$3m
Dec 31 2018	US$353k	US$83k	-US$3m
Sep 30 2018	n/a	n/a	-US$2m
Jun 30 2018	n/a	n/a	-US$2m
Mar 31 2018	n/a	n/a	-US$2m
Dec 31 2017	US$48k	n/a	-US$2m

報酬と市場: Davidの総報酬 ($USD 384.20K ) は、 US市場 ($USD 647.72K ) の同様の規模の企業の平均を下回っています。

報酬と収益: Davidの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

David Dodd (74 yo)

6.2yrs

在職期間

US$384,200

報酬

Mr. David Alan Dodd has been the Chief Executive Officer and President of Geovax Labs, Inc. since September 5, 2018 and has been its Chairman since January 01, 2011 and Director since March 17, 2010. Mr. D...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
David Dodd	Chairman	6.2yrs	US$384.20k	0.28% $ 78.6k
Mark Newman	Chief Scientific Officer	4.3yrs	US$291.50k	0% $ 0
Kelly McKee	Chief Medical Officer	2.8yrs	US$361.03k	0.025% $ 7.0k
Harriet Robinson	Founder	no data	データなし	データなし
Mark Reynolds	CFO & Corporate Secretary	18.1yrs	US$421.40k	0.076% $ 21.3k
Thomas O'Brien	Vice President of Quality Systems & Compliance	no data	データなし	データなし
Jeffrey Welch	Head of Process Development & Manufacturing Operations	2.7yrs	データなし	データなし
John Niles	Head of Commercial Operations	no data	データなし	データなし
John Sharkey	Vice President of Business Development	2.4yrs	データなし	データなし

3.5yrs

平均在職期間

71.5yo

平均年齢

経験豊富な経営陣: GOVXの経営陣は経験豊富であると考えられます ( 3.5年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
David Dodd	Chairman	14.7yrs	US$384.20k	0.28% $ 78.6k
Harriet Robinson	Founder	no data	データなし	データなし
Randal Chase	Independent Director	9.7yrs	US$47.50k	0.026% $ 7.2k
John Spencer	Independent Director	18.2yrs	US$45.00k	0.015% $ 4.1k
Robert McNally	Independent Director	17.9yrs	US$47.50k	0.038% $ 10.6k
Stanley Plotkin	Member of Scientific Advisory Board	no data	データなし	データなし
Dean Kollintzas	Independent Director	18.2yrs	US$37.50k	0.0085% $ 2.4k
Barney Graham	Member of Scientific Advisory Board	no data	データなし	データなし
Scott Weaver	Member of Scientific Advisory Board	no data	データなし	データなし
Olivera Finn	Member of Scientific Advisory Board	no data	データなし	データなし
Nicole Lemerond	Independent Director	2.3yrs	US$32.50k	0% $ 0
Jayne Morgan	Independent Director	1.9yrs	US$30.00k	0% $ 0

14.7yrs

平均在職期間

74yo

平均年齢

経験豊富なボード: GOVXの取締役会は経験豊富で経験豊富です ( 14.7年の平均在任期間)。

GeoVax Labs マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

GeoVax Labs, Inc., Annual General Meeting, May 23, 2024

Geovax Appoints Marc Pipas as Executive Medical Director, Oncology

GeoVax Labs, Inc., Annual General Meeting, Aug 01, 2023

Geovax Labs, Inc. Appoints Valerie Montgomery Rice as Special Advisor to the Chairman/CEO and Board of Directors

GeoVax Labs, Inc. Appoints Jayne Morgan to Board of Directors

High number of new directors

Recent updates

GeoVax Labs, Inc. Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia

GeoVax Labs Regains Compliance with Nasdaq's Minimum $2.5 Million Stockholders’ Equity Requirement Pursuant to Nasdaq Listing Rule 5550(b)(1)

GeoVax Labs, Inc. to Report Q3, 2024 Results on Nov 12, 2024

GeoVax Labs, Inc. has filed a Follow-on Equity Offering in the amount of $4.486846 million.

GeoVax Labs, Inc. has filed a Follow-on Equity Offering in the amount of $5.000001 million.

GeoVax Labs, Inc. has filed a Follow-on Equity Offering in the amount of $8.499997 million.

GeoVax Labs, Inc. has filed a Follow-on Equity Offering in the amount of $8.499997 million.

GeoVax Labs, Inc. has filed a Follow-on Equity Offering in the amount of $8.5 million.

Geovax Labs, Inc. Announces Phase 2 Plans for Gedeptin®? Cancer Therapy Following Clinical Advisory Committee Review

GeoVax Labs, Inc. to Report Q2, 2024 Results on Aug 06, 2024

GeoVax Labs Receives Letter from Nasdaq Due to Failure to Comply with Nasdaq’s Shareholder Approval Requirements Set Forth in Nasdaq Listing Rule 5635(d)

GeoVax Labs Receives a Notice from Nasdaq Regarding Non-Compliance with Minimum $2.5 Million Stockholders’ Equity Requirement Pursuant to Nasdaq Listing Rule 5550(b)(1)

Price target increased by 14% to US$120

GeoVax Labs, Inc. to Report Q1, 2024 Results on May 14, 2024

GeoVax Labs, Inc., Annual General Meeting, May 23, 2024

GeoVax Labs, Inc. to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress

GeoVax Labs, Inc. Achieves Milestone in Transition to Commercially Validated Manufacturing System

New minor risk - Shareholder dilution

Price target increased by 14% to US$120

GeoVax Labs, Inc. to Report Q4, 2023 Results on Feb 29, 2024

GeoVax Labs Regains Compliance with Nasdaq Minimum Bid Requirement

Geovax Reports Positive Interim Data from Phase 2 Clinical Trial of Geo-Cm04s1 as A Universal Covid-19 Vaccine Booster

GeoVax Announces 1 for 15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement

Geovax Appoints Marc Pipas as Executive Medical Director, Oncology

New major risk - Market cap size

GeoVax Labs Receives a Notice from the Nasdaq Stock Market

Geovax Labs, Inc. Announces the Presentation of Preclinical Vaccine Efficacy Data for GEO-CM02

New major risk - Revenue and earnings growth

GeoVax Labs, Inc. to Report Q3, 2023 Results on Nov 08, 2023

GeoVax Labs, Inc. Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine

Geovax Labs, Inc. Next-Generation Covid-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients

GeoVax Labs, Inc. Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster

New major risk - Financial position

GeoVax Labs, Inc. Announces First Patients Vaccinated in Phase 2 Clinical Trial of Covid-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia

GeoVax Labs, Inc. to Report Q2, 2023 Results on Aug 09, 2023

GeoVax Labs, Inc. Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia

GeoVax Labs, Inc., Annual General Meeting, Aug 01, 2023

GeoVax Labs, Inc. Announces Next-Generation COVID-19 Vaccine Data to Be Presented At Two Upcoming Scientific Meetings

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers

Geovax Labs, Inc. Appoints Valerie Montgomery Rice as Special Advisor to the Chairman/CEO and Board of Directors

GeoVax Labs Receives Non-Compliance Notice From Nasdaq

GeoVax Labs, Inc. Appoints Jayne Morgan to Board of Directors

Price target decreased to US$5.50

Third quarter 2022 earnings released: US$0.17 loss per share (vs US$0.31 loss in 3Q 2021)

High number of new directors

GeoVax Labs, Inc. to Report Q3, 2022 Results on Nov 09, 2022

We Think GeoVax Labs (NASDAQ:GOVX) Needs To Drive Business Growth Carefully

Geovax Announces Appointment of Nicole Lemerond to Its Board of Directors

GeoVax: Possible Vaccine Advancements In 2 Big Indications

Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.21 loss in 2Q 2021)

GeoVax adds 16% as journal publishes animal study on ebolavirus vaccine

GeoVax Labs, Inc. to Report Q2, 2022 Results on Aug 03, 2022

GeoVax Labs, Inc., Annual General Meeting, Aug 03, 2022

Companies Like GeoVax Labs (NASDAQ:GOVX) Could Be Quite Risky

First quarter 2022 earnings released: US$0.34 loss per share (vs US$0.29 loss in 1Q 2021)

Insufficient new directors

GeoVax Labs, Inc. to Report Q1, 2022 Results on Apr 27, 2022

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Geovax Labs, Inc. Announces Management Appointments

GeoVax Labs, Inc. to Report Fiscal Year 2021 Results on Mar 09, 2022

GeoVax Labs, Inc. announced that it has received $9.999998 million in funding

GeoVax: A Legitimate COVID-19 Phase 2 Vaccine Candidate Trading At Only A $25 Million Valuation

GeoVax Labs, Inc. Announces Initiation of Phase 2 Clinical Trial for Covid-19 Vaccine Booster

GeoVax Labs, Inc. Presents Hemorrhagic Fever Vaccine Data at World Vaccine & Immunotherapy Congress

We Think GeoVax Labs (NASDAQ:GOVX) Can Afford To Drive Business Growth

Third quarter 2021 earnings released: US$0.31 loss per share (vs US$0.73 loss in 3Q 2020)

GeoVax: Expands Immuno-Oncology Pipeline With Clinical-Stage Program

Geovax Presents Covid-19 Vaccine Data At the European Society of Medicine (Esmed) General Assembly

マネジメント基準チェック /44